AID351

AID351 is a **human anti-dengue virus monoclonal antibody** engineered for broad neutralizing activity against all four dengue virus serotypes (DENV-1 to DENV-4). Originally discovered by A*STAR SIgN and NUS, it was optimized by Chugai Pharmaceutical using proprietary antibody engineering technologies, including affinity maturation of the Fab region and Fc modifications (LALA/KAES) to abrogate Fcγ receptor binding—reducing antibody-dependent enhancement (ADE) risk—while preserving or enhancing C1q binding for complement-mediated antiviral efficacy. It demonstrates therapeutic potential in mouse models by reducing viremia, mitigating thrombocytopenia, and improving survival post-DENV-2 infection, with favorable pharmacokinetics including extended half-life and good subcutaneous bioavailability in cynomolgus monkeys. Primarily developed for **prevention and treatment of dengue fever**, an infectious disease affecting nearly 400 million annually, AID351 is in **preclinical development** with a recent collaboration between Chugai and GSK's Global Health Unit to advance toward clinical studies.[1][2][3]

Other names

Anti-Dengue Virus Antibody